Lynparza approved in Japan for BRCA-mutated metastatic breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Merck announced Japan’s Pharmaceuticals and Medical Devices Agency has approved Lynparza (olaparib) tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2-negative breast cancer who have received prior chemotherapy. Patients are selected for therapy based on an approved companion diagnostic.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login